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Introduction. Cushing’s syndrome (CS) has repeatedly been associated with hippocampal volume reductions, while little
information is available on the amygdala, another structure rich in glucocorticoid receptors. The aim of the study was to analyze
amygdala volume in patients with CS and its relationship with anxiety, depression, and hormone levels.Material and Methods. 39
CS patients (16 active and 23 patients in remission) and 39 healthy controls matched for age, sex, and education level completed
anxiety (STAI) and depression tests (BDI-II) and underwent a 3 Tesla brain MRI and endocrine testing. Amygdala volumes were
analysed with FreeSurfer software. Results. Active CS patients had smaller right (but not left) amygdala volumes when compared
to controls (𝑃 = 0.045). Left amygdala volumes negatively correlated with depression scores (𝑟 = −0.692, 𝑃 = 0.003) and current
anxiety state scores (𝑟 = −0.617, 𝑃 = 0.011) in active CS patients and with anxiety trait scores (𝑟 = −0.440, 𝑃 = 0.036) in patients in
remission. No correlations were found between current ACTH, urinary free cortisol or blood cortisol levels, and amygdala volumes
in either patient group. Conclusion. Patients with active CS have a smaller right amygdala volume in comparison to controls, while
left amygdala volumes are associated with mood state in both patient groups.
1. Introduction
Cushing’s syndrome (CS) is a rare disease due a cortisol
excess. Its symptoms include facial plethora, muscle weak-
ness, skin symptoms (red or purple striae and easy bruising),
bone loss, cardiovascular risk factors (hypertension, diabetes
and impaired glucose tolerance, dyslipidemia, coagulopathy,
and central obesity), fatigue, lack of libido, emotional lability,
depression, anxiety, and cognitive alterations [1–5]. Even
after cure, patients can still have physical and psychological
comorbidities, which may negatively impact on quality of life
[6, 7].
Cortisol excess has been associated with structural alter-
ations of the brain. Studies in active disease have found
smaller whole brain, hippocampal, and cerebellar volumes
in comparison to controls, while there is still some contro-
versy on possible recovery after cure [8–11]. Interestingly,
less attention has been devoted to the amygdala, a brain
structure with an important role in emotional response that
is also a target area for glucocorticoid hormones through the
activation of glucocorticoid and mineralocorticod receptors
[12–15].
The few studies in CS focusing on the amygdala have
reported interesting data, part of them in children and
adolescents. Smaller amygdala volumes have been found
in children with CS when compared to controls, manually
tracing the amygdalar structure on MRI. In contrast to total
cerebral volume, this volumetric reduction did not seem to
reverse after cure [16]. In adult patients in remission, no
differences in volumes were found for amygdala using voxel
based morphometry compared to controls [13]. Regarding
functional studies, in adolescents, greater left amygdala
activation was found during face encoding tasks [17], while
in adult patients in remission no differences in amygdalar
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activation were found when processing emotional faces [18].
To our knowledge, no data are available on amygdalar volume
in adult patients with active CS.
The aim of this study was to analyze amygdala volume in
patients with CS (both active and in remission) and relate it
to anxiety, depression, hormonal levels, and both duration of
hypercortisolism and delay to diagnosis.
2. Material and Methods
2.1. Patients. The sample included 39 patients with CS (16
patients with active hypercortisolism and 23 patients in
remission) and 39 healthy controls, which were matched for
sex, age (±3 years), and years of education (±3 years). Patients
were addressed and recruited during their routine follow-ups
in the hospital. Controls were recruited from other studies
and from the blood donor’s center of the hospital. Before
enrolment, both patients and controls signed an informed
consent. The study was approved by the ethics committee of
the hospital.
Exclusion criteria for patients with CS included the
following: age above 65 years, known prior cerebrovascular
disease, severe neurological or psychiatric illness, growth
hormone (GH) deficiency, and history of drug or alcohol
abuse. For controls, the same criteria were considered, and
endocrine disease and glucocorticoid exposure were addi-
tional exclusion criteria. As usual in MRI studies, only right
handed subjects (CS patients and controls) were included
(Edinburgh Handedness Inventory > 80) [19].
Patients were divided into two categories according to
disease activity. They were considered in remission after
surgery if morning cortisol suppression (<50 nmol/l) was
observed after 1mg dexamethasone overnight [20]; if adrenal
insufficiency was demonstrated and if repeated 24 h uri-
nary free cortisol measures were within normal parameters
(<280 nmol/24 h). Patients who did not fulfil these criteria
were considered to have active CS. All patients considered in
remission met the criteria for remission for at least 6 months.
None of the active patients had undergone surgery to treat
CS, except one who recurred after initial remission of CS.
2.2. Biochemistry, Clinical Information, and Questionnaires.
Participants underwent testing for 24-hour urinary free
cortisol (determined with a commercial radioimmunoas-
say, Coat-A-Count Cortisol, and Siemens), Plasma ACTH
was measured by chemiluminiscent immunometric assay
(Immulite 2000, Siemens Healthcare Diagnostics Products
Ltd., Llanberis, UK). Serum cortisol wasmeasured by electro-
chemiluminescent immunoassay (Modular Analytics E170,
Roche Diagnostics GmbH, Mannheim, Germany).
Clinical information was obtained from the patients’
clinical files. The estimation of duration of hypercortisolism
was calculated as the months from symptom onset to the
date of remission of hypercortisolism (or current date for
active patients, where remission had not been achieved).
Delay to diagnosis was considered as the months elapsed
from symptom onset to the final diagnosis of CS.
Participants also completed two questionnaires to assess
depression and anxiety. Beck Depression Inventory II
(BDI-II) is a self-reported questionnaire to assess the severity
of depressive symptoms. It consists of 21 items (scored from
0 to 3), taking about five minutes to complete. The total score
can range from 0 to 63, and higher scores indicate higher
severity of depressive symptoms. Scores can be interpreted as
minimal depression (0–13), mild depression (14–19), moder-
ate depression (20–28), and severe depression (29–63) [21].
State Trait Anxiety Inventory (STAI) is also a self-reported
questionnaire with two subscales that evaluate state anxiety
(related to the present moment) and trait anxiety (a more
general personal characteristic). Both subscales consist of
20 items (scored from 0 to 3). The total scores for both
state and trait subscales can range from 0 to 60. For result
interpretation, total scores are transformed into percentiles or
decatypes. In this study we decided to use percentiles. Higher
scores for both total scores and percentiles correspond to
higher anxiety levels [22].
2.3. Magnetic Resonance Imaging (MRI). All participants
underwent 3 Tesla magnetic resonance imaging (MRI).
Imaging was obtained using a Philips Achieva facility (soft-
ware version 2.1.3.2) and a dedicated acquisition proto-
col (3DMPRAGE whole brain sequence; repetition time =
6.7msec; echo time = 3.1msec, 170 slices; voxel size = 0.889 ×
0.889 × 1.2).
Images were postprocessed in the Port d’Informacio´
Cient´ıfica (PIC) of the Universitat Auto`noma de Barcelona
and volumes of the left and right amygdala were obtained.
Specifically, volumetric segmentation was performed auto-
matically using FreeSurfer version 5.3 image analysis software
(http://surfer.nmr.mgh.harvard.edu/). It is composed of 170
HP blades with two quad-cores CPU (Hewlett Packard, Palo
Alto, CA), each one with 16GB of RAM, running over
Scientific Linux version 5 (https://www.scientificlinux.org/).
FreeSurfer’s processing includes removal of nonbrain tissue
using a hybrid watershed/surface deformation procedure
[23],motion correction, automatedTalairach transformation,
and segmentation of the subcortical white matter and deep
grey matter volumetric structures [24, 25]. The PICNIC tool
(https://neuroweb.pic.es) was used for postprocessing. Both
the visual check and the automated image processing were
performed by a single blinded investigator.
All volumetric scores were normalized to the esti-
mated intracranial volume of each individual, as previously
described [11].
2.4. Statistics. Statistical analysis was performed using IBM
SPSS 22 software (SPSS Inc., Chicago, IL, USA). The
Kolmogorov-Smirnov test was used to assess normal distri-
bution. For comparisons of amygdalar volumes between the
three groups (active patients, patients in remission, and con-
trols), ANOVA followed by a posthoc analysis (Bonferroni)
was used. A three-way ANOVA was used to rule out the pos-
sible effect of glucocorticoid replacement, antidepressants, or
radiotherapy on our results.
For nonnormal data comparisons (specifically for BDI-II
and STAI) the Kruskal-Wallis test was used, and the posthoc
analysis was performed with a Mann–Whitney 𝑈-test. Cor-
relations among variables were assessed using Sperman’s rho.
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Table 1: Clinical characteristics of patients with Cushing’s syndrome (CS) and controls.
CS (𝑛 = 39) Controls
(𝑛 = 39)Active
(𝑛 = 16)
In remission
(𝑛 = 23)
Age 44.1 ± 9.0 42.9 ± 10.6 42.6 ± 10.3
Sex (female/male) 14/2 19/4 33/6
Years of education 13.9 ± 2.7 13.2 ± 3.3 13.9 ± 3.3
Origin of CS (pituitary/adrenal/ectopic/AIMAH†) 10/4/1/1 20/3/0/0 —
Cortisol lowering medication
(Metyrapone/Ketoconazole/Cabergoline/Losartan) 4/8/1/1 — —
Mean length of treatment with cortisol lowering medication (months) 4.4 ± 4.2∗ — —
Hydrocortisone replacement — 8 —
Antidepressive medication 1 5 —
Recurrencies 1 3 —
Radiotherapy — 5 —
Mean duration of hypercortisolism (months) 62.2 ± 59.1 63.1 ± 34.6 —
Delay to diagnosis (months) 49.1 ± 42.7 44.4 ± 36.1 —
Mean time of biochemical cure (months) — 66.0 ± 69.0 —
Urinary free cortisol (nmol/24 h) 350.4 ± 293.1 124.8 ± 49.2 145.5 ± 88.9
∗Including the whole sample of patients taking cortisol-lowering medication except one patient with an ectopic ACTH secretion who had been taking
medication for 120 months.
†AIMAH: ACTH-independent macronodular adrenal hyperplasia.
Table 2: Mean amygdala volumes in patients and controls.
Active CS
(𝑛 = 16)
CS in remission
(𝑛 = 23)
Controls
(𝑛 = 39)
Right
amygdala
(mm3)
1975.6 ± 392.2
∗
2141.1 ± 319.4 2208.5 ± 274.9
Left amygdala
(mm3) 1757.8 ± 290.8 1884.3 ± 277.6 1901.5 ± 242.6
∗Differences between active CS patients and controls (푃 < 0.05).
For correlations including biochemical parameters (urinary
free cortisol, blood cortisol, and ACTH), patients taking
hydrocortisone were excluded from the analysis. Statistical
differences were considered significant when 𝑃 < 0.05.
3. Results
As expected from previous matching, no differences were
found for sex, age, or education level between the groups.
Table 1 summarizes their clinical and demographic charac-
teristics.
Active patients had a smaller right (but not left) amygdala
volume when compared to controls (𝑃 = 0.045). No dif-
ferences were found for amygdala volumes when comparing
patients in remission and controls. Mean amygdala volumes
can be found in Table 2. Results did not change when patients
taking antidepressives (1 in the active group, who was active
due to a recurrence of CS, and 5 in the group of patients
in remission) were excluded, together with their matched
controls, although a marginal tendency seemed to show up
for left amygdala volumes when comparing the active and the
control group (right 𝑃 = 0.035; left 𝑃 = 0.084). Results did
not change when the patient on long-termmedical treatment
for hypercortisolism and her matched control were excluded
from the analysis (right amygdala 𝑃 = 0.033; left 𝑃 = NS).
In order to rule out the possible effect of glucocorticoid
replacement, antidepressants, or radiotherapy on our results,
a three-way ANOVA including these three factors was per-
formed. The analysis revealed that none was significant for
amygdala volumes.
Regarding neuropsychological findings, both patient
groups had higher depression and anxiety scores than con-
trols (BDI-II: active 𝑃 < 0.001, in remission 𝑃 < 0.001; STAI
state state: active 𝑃 = 0.005, in remission 𝑃 = 0.019; STAI
trait: active 𝑃 = 0.001, in remission 𝑃 < 0.001). Descriptive
details on the degree of severity of anxiety and depression can
be found in Figures 1, 2(a), and 2(b).
Correlations between amygdala volumes and depression
and anxiety scores were analysed. In active CS patients, left
(but not right) amygdala volume negatively correlated with
depression scores (𝑟 = −0.692, 𝑃 = 0.003) and current
anxiety state scores (𝑟 = −0.617, 𝑃 = 0.011). In patients
in remission, left (but not right) amygdala volume negatively
correlated with anxiety trait scores (𝑟 = −0.440, 𝑃 = 0.036).
No correlations were found between amygdala volumes and
depression and anxiety scores in controls. Mean duration of
hypercortisolism anddelay to diagnosis did not correlatewith
amygdala volumes in any of the patient groups (𝑃 = NS).
A final analysis was devoted to the correlation between
amygdala volumes and biochemical results. Neither ACTH,
urinary free cortisol, nor blood cortisol levels correlated with
amygdala volumes in active patients or patients in remission.
In contrast, right amygdala volumes negatively correlated
with ACTH (𝑟 = −0.344, 𝑃 = 0.05), 24 hour-urinary free
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Figure 1: Details on the percentage of patients and controls presenting different depression scores (Beck Depression Inventory II).
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Figure 2: Details on anxiety scores (State Trait Anxiety Inventory) expressed in percentiles for patients and controls (higher percentiles
represent higher anxiety levels). STAI manual does not provide a range interpretation, so for descriptive reasons percentile scores have been
divided in four groups of percentiles. Higher scores indicate higher anxiety.
cortisol (𝑟 = −0.354, 𝑃 = 0.047), and blood cortisol (𝑟 =
−0.420, 𝑃 = 0.009) in controls.
4. Discussion
These results show that active CS patients had smaller right
amygdala volumes than controls.This suggests that glucocor-
ticoid excess due to CS may lead to amygdala volume shrink-
age, as previously reported for other brain structures, like the
hippocampus and the cerebellum [8–10]. The mechanisms
related to this shrinkage are probably multifactorial and
could include cell death (apoptosis), reduced neurogenesis,
or dendritic structure modification, among others [26–31].
The fact that smaller amygdala volumes were not found in
patients in remission leads us to hypothesize that some sort of
volumetric increasemay occur after biochemical cure. In fact,
for the hippocampus a 10% increase has been demonstrated
after disease remission [32]. Similar results have been found
for the cerebellum, where smaller grey matter volumes were
found in active patients compared to controls but did not
differ when comparing with patients in remission [9, 13, 33].
It was initially surprising to find that only the right amyg-
dala (but not the left) was smaller in the active group com-
pared to controls. However, it important to highlight that the
two amygdala structures are not equal andmay have different
roles in emotional processing [34]. Interestingly, we found
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one study in unmedicated patients with major depression
who also had smaller right amygdala volumes in comparison
to controls, while a marginal nonsignificant tendency was
found for left amygdala volumes [35]. Similarly, patients with
treatment-resistant depression and elderly depressed patients
also have smaller right (but not left) amygdala volumes in
comparison to controls [36, 37]. Therefore, mood state could
have played a role in our findings. However, due to the small
sample size, we can not rule out that volumetric differences
may also occur in the left amygdala volumes.
The fact that both active CS patients and those in remis-
sion had higher anxiety and depression levels than controls
is in line with previous findings, where both psychological
comorbidities have been described [4, 13, 38–40]. It is
important to highlight that most of the patient’s scores were
not extremely high.
For depression, mild depression scores were present in
18.8% of active patients and 30.4% of patients in remission,
while moderate depression scores were not present in the
group of active patients and only in 4.3% of patients in
remission.This was surprising since 50 to 80% of the patients
with active disease met criteria for major depression [1].
A possible explanation may be that most of the active CS
patients were on medical treatment to reduce their cortisol
levels (which has been reported to have a positive effect
on mood alterations) [41, 42], and one patient was taking
antidepressives. For patients in remission, five were also on
antidepressants, which could have prevented impairment
in mood state. Furthermore, GH deficiency, known to be
associated with depression and anxiety, was an exclusion
criterion in our study, but not in others, related to high
depression levels [43].
Regarding anxiety, no active patients or controls were
in the 91–100 percentile range (indicating the higher range
of the normal curve and therefore higher anxiety [44])
for STAI state or trait, and only 8.7% of the patients in
remission were in this range for STAI trait. Therefore, even if
mean scores were higher than controls, most of the patient’s
scores were included in the normal range. As for depression,
cortisol lowering medication may have improved previ-
ous higher anxiety status in active patients, and excluding
patients with GH deficiencymay have limited further finding
[45].
Negative correlations were found between left amygdala
volumes and depression and anxiety levels.These findings are
in line with other populations, where left amygdala volumes
have been negatively correlated with both state and trait
anxiety levels in normal population and with anxiety state
in panic disorder [46, 47]. In fact, in emotion studies, a
lateralization to the left in amygdala activation has been
reported, particularly for negative emotions, which may play
a role in our results [48]. Left amygdala volume has also
been related to perceived social support in normal subjects,
following a positive association [49].
A meta-analysis on the amygdala volume in major
depressive disorder reports smaller amygdala volumes in
patients than controls, in studies including unmedicated
patients (while normal or higher volumes than controls
have been found in medicated patients) [50]. Interestingly,
patients with active CS (where smaller amygdala volumes
were found) often do not respond properly to antidepressives
until cortisol is normalized.Therefore, even if depression was
present, medication may not be indicated until remission of
hyercortisolism [41, 42, 51].
No correlations were found between hormone levels and
amygdala volumes, while intriguingly this was observed in
normal controls. It is possible that, in normal population,
hyperactivation of the HPA axis directly affects the amygdala,
leading to a right amygdalar volume reduction. However,
in patients having suffered chronic hypercortisolism, other
mechanisms (as mood alterations) may also have been
influencing amygdala volumes. Alternatively, it is possible
that correlations were not found, as prior chronic hypercorti-
solism (even before diagnosis) could have already altered the
amygdala volume at an earlier stage, without correlationswith
current hormone levels.
Limitations of this study include the small sample size,
difficult to avoid in rare disease studies. The heterogeneity
of the sample, including patients with different etiologies
or having performed different treatments, could be a fur-
ther limitation. This again is difficult to avoid in a rare
disease like CS. We tried to reduce it by strict exclusion
criteria (including GH deficiency). Other limitations include
not having performed a complementary functional MRI
acquisition (including performance of emotional tasks) or
evaluating androgens. Finally the cross-sectional design
precluded drawing any conclusions on the longitudinal
course of amygdala volumes. Future studies should include
a follow-up of active patients to establish if the amygdala
volume increases after disease remission and include a
higher number of patients taking or not antidepressives,
in order to compare both groups. Furthermore, studies
including both structural and functional MRI at the same
time could clarify further implications of the data we
found.
5. Conclusions
In conclusion, patients with active CS (but not patients
in remission) have a smaller right amygdala volume in
comparison to controls, while left amygdala volumes are
associated with mood state in both patient groups.
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